Why is in crisis half of the description clicks because 11 million americans upwards of 4 million are receiving no treatment to their lives lost to psychosis untreated serious Mental Illness represents a huge and unnecessary loss of human potential. It also makes our more dire social mission such as random acts of violence and sheltered homelessness Substance Abuse, and the disturbing rise of the rate of suicide i want to emphasize these problems are exacerbated not by serious Mental Illness but exacerbated by serious Mental Illness. Todays historic conversation draws broadly on the expertise of people from many disciplines and experiences and perspectives our goal is to put on the table a robust set of reforms how we go about delivering treatment to persons with serious Mental Illness. The Trump Administration has already begun the process of rebuilding our treatment system this very week the president will sign fiscal year 2020 appropriations bill that makes important in the improvem
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So